###begin article-title 0
BMP-7 Does Not Protect against Bleomycin-Induced Lung or Skin Fibrosis
###end article-title 0
###begin p 1
Conceived and designed the experiments: LAM TLH DAK. Performed the experiments: LAM TLH SMW FS RLA. Analyzed the data: LAM TLH SMW FS RLA. Wrote the paper: LAM DAK. Intellectual input and review of manuscript: PD FXF.
###end p 1
###begin p 2
Current address: Promedior, Inc, Malvern, Pennsylvania, United States of America
###end p 2
###begin p 3
###xml 373 380 364 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 719 726 707 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1035 1042 1017 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1046 1054 1028 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 607 612 <span type="species:ncbi:9606">human</span>
###xml 781 786 <span type="species:ncbi:9606">human</span>
###xml 901 906 <span type="species:ncbi:9606">human</span>
Bone morphogenic protein (BMP)-7 is a member of the BMP family which are structurally and functionally related, and part of the TGFbeta super family of growth factors. BMP-7 has been reported to inhibit renal fibrosis and TGFbeta1-induced epithelial-mesenchymal transition (EMT), in part through negative interactions with TGFbeta1 induced Smad 2/3 activation. We utilized in vivo bleomycin-induced fibrosis models in the skin and lung to determine the potential therapeutic effect of BMP-7. We then determined the effect of BMP-7 on TGFbeta1-induced EMT in lung epithelial cells and collagen production by human lung fibroblasts. We show that BMP-7 did not affect bleomycin-induced fibrosis in either the lung or skin in vivo; had no effect on expression of pro-fibrotic genes by human lung fibroblasts, either at rest or following exposure to TGFbeta1; and did not modulate TGFbeta1 -induced EMT in human lung epithelial cells. Taken together our data indicates that BMP-7 has no anti-fibrotic effect in lung or skin fibrosis either in vivo or in vitro. This suggests that the therapeutic options for BMP-7 may be confined to the renal compartment.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 352 355 352 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Evans1">[1]</xref>
###xml 357 360 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zhang1">[2]</xref>
###xml 414 420 <span type="species:ncbi:9606">people</span>
Heightened activation, altered phenotype and augmented synthetic activity of collagen producing cells are hallmarks of fibrosis. In the lung, fibrotic diseases such as idiopathic pulmonary fibrosis (IPF), result in reduced lung compliance and loss of alveolar architecture, which ultimately leads to organ failure and death of the afflicted individual [1], [2]. Similarly, in the skin, a significant population of people affected by diseases such as scleroderma also have substantial fibrosis of the lungs and other internal organs. The progressive decline in organ function in these diseases is pronounced and unrelenting, due, in part, to the lack of effective treatments being available.
###end p 5
###begin p 6
###xml 131 134 128 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Gu1">[3]</xref>
###xml 135 138 132 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Kasai1">[5]</xref>
###xml 364 367 357 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Evans1">[1]</xref>
###xml 368 371 361 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Gu1">[3]</xref>
###xml 488 491 478 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Jain1">[4]</xref>
###xml 492 495 482 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Willis1">[6]</xref>
###xml 817 820 807 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Willis2">[7]</xref>
###xml 822 825 812 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Valcourt1">[8]</xref>
###xml 973 976 963 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Okada1">[9]</xref>
###xml 977 981 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Saika1">[12]</xref>
###xml 1063 1071 1053 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1076 1083 1066 1073 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1160 1163 1150 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Kasai1">[5]</xref>
###xml 1165 1169 1155 1159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Kim1">[13]</xref>
###xml 1171 1175 1161 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Willis3">[14]</xref>
###xml 98 103 <span type="species:ncbi:9606">human</span>
TGFbeta1, is the prototypical pro-fibrotic cytokine and is over-expressed in fibrosis in multiple human settings and animal models [3]-[5]. This growth factor induces excess extracellular matrix (ECM) generation, enhanced fibroblast survival and the differentiation of fibroblasts to alphaSMA-positive myofibroblasts, which are relatively absent from normal lungs [1]-[3]. Additionally, one of the more recent activities ascribed to TGFbeta1 is epithelial to mesenchymal transition (EMT) [4]-[6]. EMT is a dynamic process by which epithelial cells undergo phenotypic transition to motile mesenchymal cells such as fibroblasts and myofibroblasts and is accompanied by downregulation of epithelial proteins such as E-cadherin with a concomitant increase in mesenchymal cell markers such as vimentin and EDA-fibronectin [7], [8]. EMT has been observed in several experimental models of fibrosis where it has been shown to account for up to 20% of the interstitial fibroblasts [9]-[12]. Several recent studies have shown that EMT occurs in lung epithelial cells both in vitro and in vivo, supporting the concept of EMT contributing to the fibrosis observed in IPF [5], [13], [14]. However, intracellular processes that modify fibrotic pathways and EMT in particular, have not been evaluated.
###end p 6
###begin p 7
###xml 166 170 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Eickelberg1">[15]</xref>
###xml 323 327 320 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Derynck1">[16]</xref>
###xml 329 333 326 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Feng1">[17]</xref>
###xml 440 444 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Eickelberg1">[15]</xref>
###xml 446 450 443 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Wordinger1">[18]</xref>
###xml 540 544 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Massague1">[19]</xref>
###xml 546 550 543 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Wrana1">[20]</xref>
###xml 701 705 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Massague1">[19]</xref>
###xml 707 711 701 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Wrana1">[20]</xref>
###xml 825 829 816 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg1">[21]</xref>
###xml 872 879 863 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 879 883 870 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg2">[22]</xref>
###xml 967 971 958 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg2">[22]</xref>
###xml 1085 1088 1076 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Valcourt1">[8]</xref>
###xml 1112 1116 1103 1107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Tacke1">[23]</xref>
###xml 1310 1318 1298 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Bone morphogenic protein (BMP)-7 is a member of the BMP family which are structurally and functionally related, and part of the TGFbeta superfamily of growth factors [15]. There are three type I and three type II receptors so far identified and any two of each forms a heterotetramer receptor that BMP-7 can signal through [16], [17]. Binding of BMP-7 to its receptor complex results in recruitment and phosphorylation of Smad's 1, 5 and 8 [15], [18], which then associate with Smad 4, translocate to the nucleus and confer gene expression [19], [20]. BMP-7 has also been shown to modulate TGFbeta1 signaling, by either inhibiting Smad 2/3 phosphorylation or by direct competition for Smad 4, or both [19], [20]. Accordingly, BMP-7 has also been reported to inhibit many processes involving TGFbeta1 including renal fibrosis [21], cardiac fibrosis and allograft rejection in vivo[22] as well as EMT and at high concentrations, endothelial cell-mesenchymal transition [22]. However, in other cells, such as hepatocytes or breast epithelial cells, BMP-7 appears to have either no effect [8] or the opposite effect [23], suggesting some organ specificity. In the present study we sought to evaluate the role of BMP-7 in lung and skin fibrosis as well its capacity to regulate the pro-fibrotic effects of TGFbeta1 in vitro.
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
BMP-7 does not inhibit intratracheal bleomycin-induced pulmonary fibrosis
###end title 9
###begin p 10
###xml 491 498 488 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g001">Fig. 1A</xref>
###xml 685 692 679 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g001">Fig. 1B</xref>
###xml 138 142 <span type="species:ncbi:10090">Mice</span>
In initial experiments we correlated collagen deposition in the lung following bleomycin administration, with the expression of TGFbeta1. Mice were treated with either bleomycin or saline as a control on day 0, with cohorts being sacrificed at days 1, 2, 4, 8, 13, 16 and 21 after intratracheal challenge. There was a significant increase in total collagen deposition observed as early as 8 days post-bleomycin which continued to increase until day 16, after which levels began to decrease (Fig. 1A). Gene transcription of TGFbeta1 followed a similar pattern of induction with significant increases being noted at day 4, continuing to a maximum after 16 days and decreasing at day 21 (Fig. 1B).
###end p 10
###begin title 11
Timecourse of bleomycin-induced lung fibrosis.
###end title 11
###begin p 12
###xml 278 279 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 225 229 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 466 470 <span type="species:ncbi:10090">mice</span>
(A) Timecourse of induction of collagen protein generation in the lungs of mice challenged with intratracheal bleomycin (filled bars) or intratracheal PBS (open bars) as measured by the Sircol Assay (mean+/-S.E.M. of n = 4-8 mice/group). (B) Real-time RT-PCR analysis of TGFbeta1 (open bars) gene expression in the lungs of mice challenged with intratracheal bleomycin compared to PBS control (dotted line) at the same corresponding time points (mean value of n = 3 mice/group). For differences between bleomycin challenged and corresponding time point PBS control groups * indicates p<0.05, **p<0.01 statistical significance difference between bleomycin and corresponding time point PBS control.
###end p 12
###begin p 13
###xml 213 217 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg1">[21]</xref>
###xml 252 259 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
Due to the reported effects of BMP-7 inhibiting TGFbeta1 pathway, we systemically administered BMP-7 (500 microg/kg) to mice daily for 2 weeks. This dose level is higher than previously reported to be efficacious [21]. Therefore the amount used in the in vivo studies were supramaximal than anticipated efficacious dose levels.
###end p 13
###begin p 14
###xml 182 191 182 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g002">Figure 2A</xref>
###xml 357 364 357 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g002">Fig. 2B</xref>
###xml 757 764 757 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g002">Fig. 2C</xref>
###xml 863 870 863 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g002">Fig. 2D</xref>
###xml 995 1008 995 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g002">Fig. 2D and E</xref>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
###xml 934 938 <span type="species:ncbi:10090">mice</span>
As peak collagen synthesis occurred between day 13 and 16, mice were sacrificed on day 14 and lungs analyzed for collagen production and expression of pro-fibrotic genes. As seen in Figure 2A, we found that BMP-7 had no effect on bleomycin-induced lung collagen deposition. Administration of rhBMP-7 also induced the expression of IL-6 mRNA in lung tissue (Fig. 2B). To confirm that BMP-7 did not alter the deposition of collagen or gross pathology induced by bleomycin, we also histologically analyzed lungs from all cohorts of animals. As expected, bleomycin induced disorganization of normal alveolar architecture, pronounced collagen accumulation and interstitial infiltrates. Moreover, comparable histopathology was observed in the BMP-7-treated mice (Fig. 2C). We confirmed that BMP-7 reached the lungs we stained lung sections with an anti-BMP-7 antibody (Fig. 2D). Moreover BMP-7 was biologically active in the lungs of dosed mice as we observed increased phosphorylation of Smad 1,5,8 (Fig. 2D and E). Taken together, this indicated that BMP-7 had no protective or inhibitory effect on the fibrotic response induced by intratracheal bleomycin.
###end p 14
###begin title 15
BMP-7 does not inhibit intratracheal bleomycin-induced pulmonary fibrosis.
###end title 15
###begin p 16
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 328 332 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 567 571 <span type="species:ncbi:10090">mice</span>
(A) Total soluble collagen levels in lung homogenates from mice challenged with bleomycin or PBS (open bars) 14 days post-intratracheal administration, and treated with vehicle (filled bars) or BMP-7 (hatched bars) daily (mean+/-S.E.M. of n = 5 mice/group). (B) Real-time RT-PCR analysis of IL-6 gene expression in the lungs of mice challenged with intratracheal PBS (open bars) or bleomycin and treated daily with BMP-7 (hatched bars) or vehicle (filled bars) for 14 days (mean+/-S.E.M of n = 3 mice/group). Representative photomicrographs of sections of lungs from mice 14 days after intratracheal delivery of saline (left) or 14 days after intratracheal bleomycin and treatment with daily injections of BMP-7 (right) or vehicle control (middle). Sections are stained with (C) haematoxylin and eosin (top panels) or PicroSirius red (bottom panels); or immunostained for (D) BMP7 (top panels) or phosphor- Smad 1,5,8 (middle panels) expression or isotype control (bottom panels) Fields viewed at x200 magnification. (E) Quantification of immunostaining for the number of positive cells for BMP7 (grey bars) or phosphor- Smad 1,5,8 (black bars) in lung sections using image pro(c). Bars represent mean number of positive cells+/-S.E.M. for three sections. For differences between bleomycin and corresponding PBS control, * indicates p<0.05, **p<0.01 statistical significance.
###end p 16
###begin title 17
Systemic BMP-7 does not inhibit subcutaneous bleomycin-induced skin or lung collagen
###end title 17
###begin p 18
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Matsushita1">[24]</xref>
###xml 470 483 470 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g003">Fig. 3A and B</xref>
###xml 664 677 664 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g003">Fig. 3C and D</xref>
Another model of fibrosis involves repeated subcutaneous delivery of bleomycin [24], which results in an experiment model of systemic sclerosis characterized by increased local skin collagen deposition, as well as a subsequent increase in pulmonary collagen deposition. This mode of bleomycin delivery results in a substantial increase in skin and lung collagen production. However, systemic rhBMP-7 treatment had no effect on the deposition of collagen at either site (Fig. 3A and B). Subcutaneous bleomycin administration also increased levels of the pro-fibrotic chemokine JE/CCL2 in both the skin and lung, and this too was not inhibited by rhBMP-7 treatment (Fig. 3C and D).
###end p 18
###begin title 19
BMP-7 does not inhibit subcutaneous bleomycin-induced skin and lung fibrosis.
###end title 19
###begin p 20
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
Total collagen in the (A) skin or (B) lungs of mice challenged daily with subcutaneous bleomycin and treated daily with either BMP-7 (hatched bars) or vehicle control (filled bars) (mean+/-S.E.M. of n = 8 mice/group). JE/CCL2 protein levels were measured by luminex in (C) skin and (D) lung homogenates of subcutaneous bleomycin-challenged mice. Each data point represents one animal, with bars representing the mean. For differences in Bleomycin challenged in comparison to naive control groups * indicates p<0.05, **p<0.01, ***p<0.005 statistical significance.
###end p 20
###begin title 21
###xml 57 62 <span type="species:ncbi:9606">human</span>
BMP-7 has no effect on expression of profibrotic gene in human lung fibroblasts
###end title 21
###begin p 22
###xml 58 65 58 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 119 127 119 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 234 241 227 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g004">Fig. 4A</xref>
###xml 254 261 243 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g004">Fig. 4B</xref>
###xml 270 277 259 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g004">Fig. 4C</xref>
###xml 293 300 279 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g004">Fig. 4D</xref>
###xml 601 614 573 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g004">Fig. 4E and F</xref>
###xml 718 731 690 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g004">Fig. 4E and F</xref>
###xml 141 146 <span type="species:ncbi:9606">human</span>
Given that BMP-7 had little effect on indices of fibrosis in vivo, we asked whether BMP-7 affected fibroblast function in vitro. Exposure of human lung fibroblasts to TGFbeta1 (10 ng/ml) upregulated expression of procollagen Ialpha1 (Fig. 4A), alphaSMA (Fig. 4B), CTGF (Fig. 4C) and TGFbeta1 (Fig. 4D). Treatment with rhBMP-7 at either 10 or 50 ng/ml had no effect on expression of any of these genes, either alone or following treatment with TGFbeta1 responses. We further evaluated alphaSMA at the protein level and found that BMP-7 did not modulate baseline or TGFbeta-induced alphaSMA expression (Fig. 4E and F). Again phosphorylation of Smad 1,5,8 demonstrated that the exogenous rhBMP-7 was biologically active (Fig. 4E and F).
###end p 22
###begin title 23
###xml 30 31 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
BMP-7 does not inhibit TGFbeta1 induced gene expression in fibroblasts.
###end title 23
###begin p 24
###xml 167 168 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 279 280 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 8 13 <span type="species:ncbi:9606">human</span>
Primary human lung fibroblasts (n = 3) were serum starved for 24 hours before incubation with rhBMP-7 at 10 or 50 ng/ml for one hour and then stimulated with rhTGFbeta1 for 24 hours. Relative changes in mRNA expression of (A) procollagen-1, (B) alphaSMA, (C) CTGF and (D) TGFbeta1 were analyzed using real-time RT-PCR. Protein expression of alphaSMA and phosphoSMAD 1,5,8, was (E) visualized and (F) quantitated to beta-tubulin by Western blot analysis. * indicates p<0.05 significant difference in comparison to unstimulated cells.
###end p 24
###begin title 25
BMP-7 does not affect TGFbeta-induced epithelial to mesenchymal transition in lung epithelial cells
###end title 25
###begin p 26
###xml 307 314 301 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5A</xref>
###xml 667 680 658 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5B and C</xref>
###xml 763 770 754 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5A</xref>
###xml 927 940 915 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5B and C</xref>
###xml 1259 1272 1247 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5B and C</xref>
###xml 1401 1414 1386 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5B and C</xref>
###xml 1749 1756 1725 1732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5D</xref>
###xml 2304 2317 2274 2287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5E and F</xref>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 1946 1951 <span type="species:ncbi:9606">human</span>
Given that there appears to be some degree of differences in organ or cell specificity to BMP-7, we determined whether rhBMP-7 could influence TGFbeta1-induced EMT in the human lung epithelial cell line A549. Incubation with TGFbeta1 at either 10 or 50 ng/ml induced phenotypic changes consistent with EMT (Fig. 5A). Morphologically the cells lost their rounded cobblestone appearance and became stellate and migratory. Exposure to TGFbeta1 also induced biochemical changes such as robust expression of the mesenchymal markers EDA fibronectin (EDA-FN) and vimentin, and a concomitant downregulation of the epithelial markers E-Cadherin and zonula occludens-1 (ZO-1) (Fig. 5B and C). Addition of rhBMP-7 alone had no obvious effect on the phenotype of A549 cells (Fig. 5A). When added at the same time as TGFbeta1, rhBMP-7 (10 or 50 ng/ml) had no effect on cell morphology or expression of EDA-FN, vimentin, ZO-1 or E-Cadherin (Fig. 5B and C). BMP-7 signaling is mediated by BMP receptor II and subsequent recruitment and phosphorylation of Smad 1, 5 and 8. To confirm that BMP-7 was active, we evaluated BMP receptor II expression and Smad 1,5,8 phosphorylation by Western blot analysis. Comparable levels of BMPRII expression were seen under all conditions (Fig. 5B and C). Furthermore, BMP-7 induced a dose-dependent increase in phosphorylation of Smad 1,5,8 in the presence or absence of TGFbeta1 (Fig. 5B and C) confirming that BMP-7 signaling is activated following TGFbeta1 exposure. We also assessed whether BMP-7 interacted with TGFbeta1 signaling, by examining phosphorylation of Smad 3 and expression of Smad 3-dependent genes Snail-1 and Snail-2 (slug). Exposure to rhBMP-7 had no effect on TGFbeta1-induced expression of Snail-1 and -2 (Fig. 5D) or Smad 3 phosphorylation even when used at a supramaximal concentration of 500 ng/ml (data not shown). We extended these findings to evaluate the effect of rhBMP-7 on primary cultures of human bronchial epithelial cells and observed a similar phenomenon. In this setting, TGFbeta1 induced EMT as described above. In contrast, BMP-7 had no effect on indices of EMT and did not modify the EMT responses to TGFbeta1. This was not due to a lack of activity since we observed increased expression of phosphorylated Smad 1,5,8 in response to rhBMP-7 (Fig. 5E and F).
###end p 26
###begin title 27
###xml 30 31 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
BMP-7 does not inhibit TGFbeta1 induced EMT in A549 cells.
###end title 27
###begin p 28
###xml 159 160 156 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 287 288 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 547 548 538 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 886 887 874 875 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1104 1113 1043 1052 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Figure 5C</xref>
###xml 1334 1335 1270 1271 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1546 1555 1433 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Figure 5E</xref>
###xml 1151 1156 <span type="species:ncbi:9606">human</span>
A549 cells (n = 5) were serum starved for 24 hours before treatment with rhBMP-7 (10 or 50 ng/ml) for 24 hours followed by the presence or absence of rhTGFbeta1 (10 ng/ml). (A) Phenotypic changes by light microscopy were noted in A549 cells cultured in medium with 0.5% serum and TGFbeta1 (10 ng/ml) which were not attenuated by pre-incubation with BMP-7 at 10 or 50 ng/ml. (B) Snail-1 and Snail-2 gene expression was determined using real time RT-PCR in RNA isolated A549 cells after 48 hours of stimulation with BMP-7 (10 or 50 ng/ml) or TGFbeta1 (10 ng/ml) alone or in combination, experiments were run in triplicate. (C) Western blot analysis of A549 lysates for the mesenchymal markers Fibronectin-EDA and vimentin, an epithelial markers E-Cadherin and ZO-1, BMP receptor II and phospho- Smad 1, 5, 8 expression following stimulation with BMP-7 alone or in combination with TGFbeta1 for 48 or 72 hours. beta-actin was used as a protein loading control. (D) Densitometric analysis of EDA-Fn 50% shaded block, E-Cadherin blacksquare, square, filled and phospho- Smad 1,5,8, square expression shown in Figure 5C. (E) Western blot analysis of normal human bronchial epithelial lysates for Fibronectin-EDA, E-cadherin, phospho Smad 3, phospho Smad 1,5,8 expression following stimulation with BMP-7 alone or in combination with TGFbeta1 for 72 hours. beta-actin was used as a protein loading control. (F) Densitometric analysis of EDA-Fn 50% shaded block, E-Cadherin blacksquare, square, filled and phospho- Smad 1, 5, 8 squareexpression shown in Figure 5E.
###end p 28
###begin title 29
Gene silencing of BMP-7 does not modulate TGFbeta-induced EMT
###end title 29
###begin p 30
###xml 144 159 141 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g006">Figure 6A and C</xref>
###xml 463 470 457 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004039-g005">Fig. 5B</xref>
To further confirm that BMP-7 does not influence TGFbeta1-induced EMT, we used siRNA to knock down endogenous BMP-7 gene expression. As seen in Figure 6A and C, BMP-7 siRNA effectively decreased expression by >75%. However, despite this level of protein suppression, A549 cells still underwent EMT as judged by changes in morphology (data not shown) as well as decreased expression of E-Cadherin and increased expression of EDA-FN following exposure to TGFbeta1 (Fig. 5B).
###end p 30
###begin title 31
###xml 56 57 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
BMP-7 knock-down does not augment the ability of TGFbeta1 to induced EMT in A549 cells.
###end title 31
###begin p 32
###xml 202 203 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 405 406 399 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
(A) Representative photomicrographs of A549 cultures (n = 3) transfected with BMP-7 siRNA (10 or 50 ng/ml), or non-silencing scrambled siRNA for 24 hours followed by the presence or absence of rhTGFbeta1 (10 ng/ml) for 72 hours. (B) Western blot analysis of A549 cell lysates indicated increased expression of mesenchymal marker Fibronectin-EDA and loss of epithelial marker E-Cadherin following rhTGFbeta1 treatment which was not enhanced following endogenous knock down of BMP-7. (C) Western blot analysis of BMP-7 showed efficient knock down of the protein following BMP-7 siRNA treatment.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 117 124 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 331 339 325 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 183 188 <span type="species:ncbi:9606">human</span>
###xml 303 308 <span type="species:ncbi:9606">human</span>
In the current study, we show that rhBMP-7: (1) did not affect bleomycin-induced fibrosis in either the lung or skin in vivo; (2) had no effect on expression of pro-fibrotic genes by human lung fibroblasts, either at rest or following exposure to TGFbeta1; (3) did not modulate TGFbeta1 -induced EMT in human lung epithelial cells in vitro. Taken together, these data suggest BMP-7 has little effect on fibrosis in the lung or the skin.
###end p 34
###begin p 35
###xml 139 142 136 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Gu1">[3]</xref>
###xml 144 148 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Cutroneo1">[25]</xref>
###xml 149 153 146 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Wu1">[27]</xref>
###xml 754 758 745 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg2">[22]</xref>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
###xml 728 734 <span type="species:ncbi:10090">murine</span>
###xml 1037 1041 <span type="species:ncbi:10090">mice</span>
Previous studies have shown that bleomycin induces collagen deposition and that TGFbeta1 plays an important role in mediating this process [3], [25]-[27]. In keeping with these findings, we found increased TGFbeta1 expression that correlated with the increase in pulmonary collagen deposition following intra-tracheal bleomycin exposure. We also found increased BMP-7 protein expression following intratracheal bleomycin, however we hypothesized that the magnitude of BMP-7 induction is insufficient to modulate TGFbeta1 activity in the lung. Therefore, to test this hypothesis we treated mice with daily injections of rhBMP-7 after bleomycin challenge. We chose a dose greater than previously demonstrated to be efficacious in murine models of fibrosis [22]. However, despite continual treatment for 14 days, the progression of lung fibrosis was not modified, suggesting that in lung cells, the inhibitory effects of BMP-7 are absent. Further, in our study there was increased IL-6 in the lungs of rhBMP-7 treated, bleomycin-challenged mice, indicating bioactive BMP-7. Also, immunohistochemical staining of lung sections from BMP-7 treated, bleomycin challenged animals showed increased phosphorylated Smad 1,5,8, indicating intact BMP-7 signaling. Therefore BMP-7, although active, was not therapeutic in our models of lung fibrosis at the efficacious doses used in this study.
###end p 35
###begin p 36
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Lakos1">[28]</xref>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Yamamoto1">[30]</xref>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
###xml 522 526 <span type="species:ncbi:10090">mice</span>
In order to further test this hypothesis, we examined whether rhBMP-7 could ameliorate skin fibrosis induced by subcutaneous administration of bleomycin. However, as was seen in the lung fibrosis model, rhBMP-7 exerted no therapeutic benefit on collagen deposition in the skin. Given that subcutaneous bleomycin also results in lung fibrosis, akin to scleroderma-associated lung fibrosis [28]-[30], we examined the lungs of the mice involved in the dermal fibrosis study and found fibrosis that was indistinguishable from mice not exposed to rhBMP-7. Similarly, secretion of the pro-fibrotic chemokine JE/CCL2 in either lung or the skin was not modified by rhBMP-7. Based on this evidence we conclude that systemic BMP-7 treatment did not reduce lung or skin fibrosis.
###end p 36
###begin p 37
###xml 114 118 114 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg1">[21]</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg3">[31]</xref>
###xml 486 489 483 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Valcourt1">[8]</xref>
###xml 611 618 601 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 820 824 806 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Tacke1">[23]</xref>
###xml 1204 1208 1190 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Maric1">[32]</xref>
###xml 1389 1393 1375 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg2">[22]</xref>
###xml 448 453 <span type="species:ncbi:10090">mouse</span>
###xml 458 463 <span type="species:ncbi:9606">human</span>
###xml 965 970 <span type="species:ncbi:9606">human</span>
###xml 1020 1024 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 1311 1316 <span type="species:ncbi:10090">mouse</span>
Thus, while there is ample data to suggest that BMP-7 has potent anti-fibrotic effects on cells within the kidney [21], [31], the data from our current experiments suggests that BMP-7 has little effect in modifying fibrosis in either the lung or the skin. Indeed, the anti-fibrotic effects of BMP-7 in extra-renal tissues remain controversial. For example, Valcourt and colleagues undertook an extensive analysis of TGFbeta1-induced EMT in several mouse and human epithelial cell lines [8]. The authors showed that except for alphaSMA expression, BMP-7 was ineffective at reversing TGFbeta1 induced EMT. In our in vivo studies, we found that alphaSMA was the only gene evaluated whose expression trended towards an inhibition with rhBMP-7 treatment (data not shown) and this supported this finding. Tacke and co-workers [23] recently demonstrated that BMP-7 induced collagen and fibronectin production by hepatic stellate cells and was upregulated in the cirrhotic human liver. In contrast, Maric et al., showed that in rats with inflammatory bowel disease, systemic administration of BMP-7 led to less severe colitis with preserved histology and suppression of pro-inflammatory and pro-fibrogenic genes [32]. More recently, administration of rhBMP-7 was shown to inhibit the progression of cardiac fibrosis in mouse models of pressure overload hypertrophy and chronic allograft rejection [22]. The reasons underlying these dichotomous responses are unknown at present, but clearly warrant further investigation.
###end p 37
###begin p 38
###xml 229 233 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg1">[21]</xref>
###xml 235 239 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg2">[22]</xref>
###xml 241 245 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Maric1">[32]</xref>
###xml 363 371 360 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 411 418 408 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 418 421 415 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Jain1">[4]</xref>
###xml 423 427 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Kim1">[13]</xref>
###xml 1947 1951 1926 1930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg1">[21]</xref>
###xml 1953 1957 1932 1936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg4">[33]</xref>
###xml 2094 2098 2073 2077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Zeisberg2">[22]</xref>
###xml 347 351 <span type="species:ncbi:10090">mice</span>
###xml 356 362 <span type="species:ncbi:9606">humans</span>
###xml 1229 1234 <span type="species:ncbi:9606">human</span>
The anti-fibrotic effects of BMP-7 in renal, gastrointestinal and cardiac fibrosis have been associated with the ability of this protein to attenuate TGFbeta1-induced epithelial or endothelial cell to mesenchymal cell transition [21], [22], [32]. We took advantage of these observations since EMT has been shown in lung epithelial cells from both mice and humans in vitro and also following bleomycin challenge in vivo[4], [13]. Exposure to TGFbeta1 induced morphological characteristics of EMT, such as elongation and cell spreading and this was associated with phosphorylation of Smad 2/3. Addition of BMP-7 at 3 different concentrations was unable to modify these effects of TGFbeta1. This was not due to lack of activity since we saw robust phosphorylation of Smad 1,5,8 in response to BMP-7. To investigate the mechanisms behind this lack of effect further we used two different strategies. Firstly we examined the effect of BMP-7 on TGFbeta1-dependent Smad 2/3 activation and the Smad 3-dependent expression of Snail-1 and Snail-2. We show that BMP-7 does not influence Smad-3 phosphorylation nor the induction of Snail-1 and -2 alone or following TGFbeta1 exposure. We confirmed this finding in primary cultures of normal human bronchial epithelial cells. In these cells, addition of rhBMP-7 had no effect on epithelial cell morphology or indices of cell signaling and did not modulate TGFbeta1-induced EMT, despite inducing robust phosphorylation of Smad 1,5,8. In the final set of experiments, we used targeted siRNA to selectively knockdown BMP-7 expression. This strategy also had no effect on TGFbeta1-driven EMT. These three independent streams of data provide further evidence for a lack of effect of BMP-7 in pro-fibrotic processes in lung epithelial cells. This hypothesis of tissue specificity is reinforced by the fact that we used a similar concentration range of BMP-7 (10 and 50 ng/ml) to that used by Zeisberg and colleagues [21], [33] to potently inhibit EMT in proximal tubular epithelial cells (10 and 100 ng/ml). Further evidence is provided by Kalluri and colleagues [22] in which effective doses of 1000 ng/ml of BMP-7 were required to inhibit endothelial-mesenchymal transition in the heart. However in our studies, supramaximal concentration of BMP-7 (500 ng/ml) also had no modulatory effect on TGFbeta1-induced EMT.
###end p 38
###begin p 39
###xml 220 224 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Gauldie1">[34]</xref>
###xml 226 230 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Vallance1">[35]</xref>
Another cell intimately linked with the development of fibrosis is the fibroblast. In these cells, TGFbeta1 mediates a variety of pro-fibrotic features including enhancing collagen production and growth factor synthesis [34], [35]. Consistent with the epithelial cell data, BMP-7 had no effect on these cells, either alone or following TGFbeta1- mediated changes in gene expression.
###end p 39
###begin p 40
###xml 99 106 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 110 118 110 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 307 311 307 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Karsenty1">[36]</xref>
###xml 267 271 <span type="species:ncbi:10090">mice</span>
Taken together we have shown that BMP-7 has no anti-fibrotic effect in lung fibrosis either at the in vivo or in vitro level. This suggests that the therapeutic options for BMP-7 may be confined to the renal compartment. This is supported by the fact that BMP-7 null mice die perinatally from renal failure [36].
###end p 40
###begin title 41
Materials and Methods
###end title 41
###begin title 42
Animal models of fibrosis
###end title 42
###begin p 43
###xml 262 272 262 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ad libitum</italic>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Burdick1">[37]</xref>
###xml 457 461 457 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Keane1">[38]</xref>
###xml 1446 1450 1430 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Ozkaynak1">[39]</xref>
###xml 1596 1603 1580 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 171 175 <span type="species:ncbi:10090">Mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">Mice</span>
###xml 1100 1104 <span type="species:ncbi:10090">mice</span>
###xml 1197 1201 <span type="species:ncbi:10090">mice</span>
###xml 1365 1369 <span type="species:ncbi:10090">mice</span>
###xml 1403 1408 <span type="species:ncbi:10090">mouse</span>
###xml 1413 1416 <span type="species:ncbi:9606">man</span>
###xml 1478 1483 <span type="species:ncbi:9606">human</span>
###xml 1537 1543 <span type="species:ncbi:10090">murine</span>
###xml 1625 1630 <span type="species:ncbi:9606">human</span>
###xml 1644 1649 <span type="species:ncbi:10090">mouse</span>
All experiments were conducted under Centocor IACUC regulations and protocols. Female C57Bl/6 mice (6-8 wk old) were purchased from ACE Laboratories (Boyertown, PA, USA). Mice were maintained in specific pathogen-free conditions and provided with food and water ad libitum. To induce intratracheal bleomycin-induced pulmonary fibrosis, mice were treated with intratracheal bleomycin (Blenoxane, Sigma, St. Louis, MO) on day 0, as previously described [37], [38]. Briefly, mice were anesthetized by intraperitoneal injection of 250 microl of 12.5 mg/ml ketamine followed by intratracheal instillation of 0.04 U of bleomycin in 50 microl of sterile PBS. Mice were analyzed for up to 21 days after bleomycin administration. Control animals received intratracheal sterile saline. For the studies evaluating the effect of BMP-7 on bleomycin-induced lung fibrosis, animals challenged with bleomycin were separated into two groups where they received vehicle control (20 mM acetate, pH 4.5 and 5% mannitol) or BMP-7 (500 microg/kg, i.p). For the subcutaneous bleomycin-induced skin and lung fibrosis model, mice backs were shaved and bleomycin administered subcutaneously daily for over 2 weeks. Control mice were injected daily with BMP-7 (500 microg/kg, i.p) or vehicle control (20 mM acetate, pH 4.5 and 5% mannitol) or PBS in the same anatomical site as the bleomycin mice. BMP-7 is well conserved between mouse and man (98% at the amino acid level [39]). Further, the recombinant human form has been used in several previous studies using murine models. Therefore in the present study, as in prior in vivo studies, we utilized human BMP-7 in our mouse models.
###end p 43
###begin title 44
Histology
###end title 44
###begin p 45
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 122 123 122 123 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 218 225 218 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">en bloc</italic>
###xml 812 813 812 813 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 814 815 814 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 848 852 <span type="species:ncbi:9925">goat</span>
###xml 868 873 <span type="species:ncbi:10090">mouse</span>
###xml 879 884 <span type="species:ncbi:9606">human</span>
###xml 892 898 <span type="species:ncbi:9986">rabbit</span>
###xml 958 964 <span type="species:ncbi:9986">rabbit</span>
###xml 1043 1049 <span type="species:ncbi:9986">rabbit</span>
###xml 1140 1144 <span type="species:ncbi:9925">goat</span>
###xml 1201 1205 <span type="species:ncbi:9925">goat</span>
###xml 1211 1217 <span type="species:ncbi:9986">rabbit</span>
Lungs were perfused in situ through the right ventricle with saline and then inflated under a constant pressure of 30 cm H2O with 1a ml of 10% normal buffered formalin (NBF). Lungs were ligated at the trachea, removed en bloc, and immersed in NBF for 24 hr. After which, tissue samples were changed to 70% alcohol before paraffin embedding, followed by sectioning, hematoxylin and eosin or Sirius Red staining. Sections were examined using a Fisher Scientific Micromaster inverted microscope and camera (Pittsburgh, PA, USA). For immunohistochemical analysis, five slides from each group containing 3 mice were stained separately to identify BMP-7 and phospho- Smad 1, 5, 8. Sections were de-paraffinized and rehydrated, and subject to antigen retrieval Subsequently, endogenous peroxidase was quenched with 3% H2O2 and blocked for 20 min with 50% goat serum. Primary mouse anti human BMP-7 (rabbit polyclonal, abcam, Cambridge, MA) and phospho- Smad 1,5,8 (rabbit polyclonal, Cell SignalingTechnology, Denvers, MA) or isotype control (normal rabbit IgG, Santa Cruz Biotechnologies, Santa Cruz, CA) were added overnight at 4degreesC in 25% goat serum. Sections were then incubated with a biotinylated goat anti-rabbit secondary antibody (Vector Labs Burlingame, CA) for 60 min followed by a 10 min treatment with Streptavidin-HRP (Dako, Mississauga, ON). The antigen of interest was visualized by using the brown chromogen 3,3-diaminobenzidine (Dako, Mississauga, ON) and counterstained with Harris Hematoxylin Solution (Sigma, Oakville, ON). Sections were then dehydrated and mounted with Cytoseal 60 (Richard-Allan Scientific, Kalamazoo, MI). Antibody dilutions and all washes were in TRIS-buffered saline solution.
###end p 45
###begin p 46
For analysis all images were viewed and captured at 200x magnification. Five randomly selected digital 425x425 micron fields per slide were obtained with the use of a light microscope (Nikon Microphoto) equipped with a digital camera (JVC3-CCD KY F-70, Diagnostic Instruments). The same field was used to identify total cells and cells expressing BMP-7 and phosphor- Smad 1,5,8. Image analysis was performed using Image-Pro Plus (Media Cybernetics, Silver Spring, Maryland).
###end p 46
###begin title 47
Tissue preparation for protein and RNA analyses
###end title 47
###begin p 48
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Burdick1">[37]</xref>
###xml 769 775 757 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">as per</italic>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
###xml 1048 1052 <span type="species:ncbi:10090">mice</span>
For protein analysis, lungs from all groups of mice were homogenized in complete protease inhibitor (Roche Diagnostics Corp, Indianapolis, Indiana, USA) as previously described [37]. Homogenates were centrifuged at 900xg for 10 minutes and frozen at -80degreesC until time of analysis. For RNA analysis, lungs were removed, homogenized in PBS and RNA was isolated using RNeasy Plus Mini-Kits (QIAGEN, Valencia, CA). Purified RNA was treated with DNAse and reverse transcribed into cDNA using TaqMan(R) Reverse Transcription Reagents (Applied Biosystems, Foster City, CA). Gene expression was determined by real-time PCR using the Taqman(R) Universal PCR Master Mix (Applied Biosystems) and pre-developed Taqman(R) Gene Expression Assays designed by Applied Biosystems, as per manufacturer's instructions. Fold induction was determined after calibration of the gene of interest with 18S rRNA and normalization to either saline control gene expression or for the effect of BMP-7 treatment, after normalization to vehicle control bleomycin-challenged mice.
###end p 48
###begin p 49
For skin fibrosis studies, on the day after the final bleomycin injection, the skin at the injection site was removed by using an 8 mm dermal biopsy punch (Miltex, York PA) and processed for protein or RNA as described above.
###end p 49
###begin title 50
Sircol Collagen assay
###end title 50
###begin p 51
###xml 116 120 116 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Blease1">[40]</xref>
###xml 312 313 308 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 516 522 512 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">as per</italic>
The Sircol collagen assay (Biocolor Ltd., Belfast, Ireland) was performed following the manufacturer's instructions [40]. Briefly, Sirius red reagent was added to each lung homogenate (50 microl) and mixed for 30 minutes at room temperature. The collagen-dye complex was precipitated by centrifugation at 16,000 g for 5 minutes and the pellet was resuspended in 1 ml of 0.5 M NaOH. The concentration of collagen in each sample was measured as absorbance at 540 nm and values extrapolated from a known standard curve as per manufacturer's instructions. Chemokine levels were measured using luminex technology (Biosource, Invitrogen, Carlsbad, CA).
###end p 51
###begin title 52
Fibroblast and epithelial protein and gene expression
###end title 52
###begin p 53
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004039-Hogaboam1">[41]</xref>
###xml 572 573 572 573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 771 772 765 766 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 895 896 886 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 67 72 <span type="species:ncbi:9606">human</span>
###xml 833 838 <span type="species:ncbi:9606">human</span>
Pulmonary fibroblasts were isolated from lung tissue obtained from human transplant donor lungs deemed unsuitable for transplantation (n = 4) and donated for medical research obtained through the International Institute for the Advancement of Medicine (Edison, NJ). The ethic committees of the involved institutions approved this study. All fibroblast cell lines were isolated by serial passaging and purity assessed using morphological and immunohistochemical staining as previously described [41]. Fibroblasts were plated into 6 well plates (Costar, Corning, NY) at 1x105 cells/well and allowed to adhere for 8 hours. The cells were then washed with PBS and cultured overnight in serum free DMEM media containing 1% penicillin and 1% streptomycin at 37degreesC in 5% C02/air. Cells were then stimulated with or without recombinant human BMP-7 (rhBMP-7; RnDSystems, Minneapolis, USA) or TGFbeta1 (Santa Cruz Biotechnology, USA), or both combined at 10 and 50 nM concentrations for 24 hrs. Supernatants were removed and RNA was subsequently isolated and analyzed by real-time PCR as described above. Here, fold induction was determined after calibration of the gene of interest with 18S rRNA and normalized to corresponding unstimulated cells. Epithelial Snail 1 and Snail 2 gene expression was evaluated in A549 cells stimulated with BMP-7 or TGFbeta1 alone or in combination. Protein levels of alphaSMA and phospho- Smad 1,5,8 were analyzed by Western analysis and normalized to beta-tubulin which served as the loading control.
###end p 53
###begin title 54
EMT Analysis
###end title 54
###begin p 55
###xml 399 400 393 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 570 571 561 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 244 250 <span type="species:ncbi:9913">bovine</span>
Experiments were performed in the A549 cell line and normal bronchial epithelial cells (NHBE; Lonza Canada Inc, Shawinigan) both grown to 60% confluence in 6 well plates (Costar, Corning, NY). A549 cells were grown in DMEM containing 10% fetal bovine serum and NHBE cells grown in bronchial epithelial growth media (BEGM, Cambrex, Lonza Canada Inc). All cultures were maintained at 37degreesC, 5% CO2/air. Prior to each experiment, cells were incubated in respective serum free media for 24 hrs. A549 and NHBE cells were then incubated with or without rhBMP-7 or TGFbeta1 or both combined at 10 and 50 nM concentrations for 48 and 72 hrs. Following this, cells were lysed in complete protease inhibitor (Roche Diagnostics Corp). Lysates at a concentration of 50 ng/ml were then electrophoresed in SDS-polyacrylamide gels, electrotransferred to nitrocellulose, and membranes underwent Western analysis with antibodies directed against fibronectin-EDA (MAB1940,Chemicon International, Temecula, USA), E-Cadherin (Clone G 10, Santa Cruz Biotechnology, USA); phospho- Smad 1,5, & 8, (AB3848) BMP receptor II (MAB3551), and rhBMP-7 (RnD Systems). beta-tubulin (Upstate, Lake Placid, NY) was used and protein loading control.
###end p 55
###begin title 56
BMP-7 knock-down with SiRNA
###end title 56
###begin p 57
###xml 304 305 298 299 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 425 426 416 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 271 277 <span type="species:ncbi:9913">bovine</span>
A549 cells grown to 50% confluence in six well plates were transfected with ON-TARGET plus SMART pool BMP-7 SiRNA (Dharmacon, Chicago, USA) or non-silencing control siRNA at a final concentration of 10 or 50 nM using Hyperfect (Quiagen, USA) in DMEM containing 10% fetal bovine serum at 37degreesC, 5% C02. After 24 hrs, cells were incubated in DMEM containing 0.5% serum for a further 24 hrs, and then incubated with TGFbeta1at 10 nM for 48 hrs. Cells were then lysed and analyzed by Western blot as above.
###end p 57
###begin title 58
Statistical analysis
###end title 58
###begin p 59
All statistical analysis were calculated using GraphPad Prism software (San Diego, CA). All statistical comparisons were performed using nonparametric Mann Whitney t-test. Data was considered significant if p<0.05, p<0.01 or p<0.005, which is referred to as *, ** or *** respectively.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins.
###end article-title 61
###begin article-title 62
Lung fibroblast alpha-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis.
###end article-title 62
###begin article-title 63
Effect of TGF-beta/Smad signaling pathway on lung myofibroblast differentiation.
###end article-title 63
###begin article-title 64
Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1.
###end article-title 64
###begin article-title 65
###xml 18 23 <span type="species:ncbi:9606">human</span>
TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT).
###end article-title 65
###begin article-title 66
TGF-beta-induced EMT: mechanisms and implications for fibrotic lung disease.
###end article-title 66
###begin article-title 67
TGF-{beta}-induced EMT: mechanisms and implications for fibrotic lung disease.
###end article-title 67
###begin article-title 68
TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition.
###end article-title 68
###begin article-title 69
Early role of Fsp1 in epithelial-mesenchymal transformation.
###end article-title 69
###begin article-title 70
Evidence that fibroblasts derive from epithelium during tissue fibrosis.
###end article-title 70
###begin article-title 71
Epithelial-mesenchymal transition and its implications for fibrosis.
###end article-title 71
###begin article-title 72
Smad3 Signaling Is Required for Epithelial-Mesenchymal Transition of Lens Epithelium after Injury.
###end article-title 72
###begin article-title 73
Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix.
###end article-title 73
###begin article-title 74
Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis.
###end article-title 74
###begin article-title 75
Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension: remodeling revisited.
###end article-title 75
###begin article-title 76
TGF-beta receptor signaling.
###end article-title 76
###begin article-title 77
Specificity and versatility in tgf-beta signaling through Smads.
###end article-title 77
###begin article-title 78
Bone morphogenetic proteins and their receptors in the eye.
###end article-title 78
###begin article-title 79
How cells read TGF-beta signals.
###end article-title 79
###begin article-title 80
Regulation of Smad activity.
###end article-title 80
###begin article-title 81
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.
###end article-title 81
###begin article-title 82
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis.
###end article-title 82
###begin article-title 83
###xml 44 52 <span type="species:ncbi:9606">patients</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells.
###end article-title 83
###begin article-title 84
###xml 53 59 <span type="species:ncbi:10090">murine</span>
Upregulation of interleukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.
###end article-title 84
###begin article-title 85
Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression.
###end article-title 85
###begin article-title 86
Receptor-activated Smad localisation in bleomycin-induced pulmonary fibrosis.
###end article-title 86
###begin article-title 87
###xml 166 171 <span type="species:ncbi:10090">mouse</span>
Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse.
###end article-title 87
###begin article-title 88
###xml 45 49 <span type="species:ncbi:10090">mice</span>
Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet.
###end article-title 88
###begin article-title 89
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma.
###end article-title 89
###begin article-title 90
###xml 93 98 <span type="species:ncbi:9606">human</span>
Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts.
###end article-title 90
###begin article-title 91
Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney.
###end article-title 91
###begin article-title 92
###xml 134 138 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Bone morphogenetic protein-7 reduces the severity of colon tissue damage and accelerates the healing of inflammatory bowel disease in rats.
###end article-title 92
###begin article-title 93
Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition.
###end article-title 93
###begin article-title 94
TGF-beta, Smad3 and the process of progressive fibrosis.
###end article-title 94
###begin article-title 95
###xml 31 36 <span type="species:ncbi:10090">mouse</span>
TGF-beta1 gene transfer to the mouse colon leads to intestinal fibrosis.
###end article-title 95
###begin article-title 96
BMP 7 is required for nephrogenesis, eye development, and skeletal patterning.
###end article-title 96
###begin article-title 97
CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling.
###end article-title 97
###begin article-title 98
IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis.
###end article-title 98
###begin article-title 99
###xml 0 6 <span type="species:ncbi:10090">Murine</span>
Murine osteogenic protein (OP-1): high levels of mRNA in kidney.
###end article-title 99
###begin article-title 100
###xml 16 20 <span type="species:ncbi:10090">mice</span>
Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma.
###end article-title 100
###begin article-title 101
###xml 87 93 <span type="species:ncbi:10090">murine</span>
Differential monocyte chemoattractant protein-1 and chemokine receptor 2 expression by murine lung fibroblasts derived from Th1- and Th2-type pulmonary granuloma models.
###end article-title 101
###begin p 102
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 102
###begin p 103
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: The work in this manuscript was supported by Centocor, Inc and operating funds from the Canadian Institutes for Health Research; the Wolfe and Gita Churg Foundation and an endowment from the Rashpal Dhillon family to DAK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 103

